| Year |
Citation |
Score |
| 2010 |
Ho MK, Goldman D, Heinz A, Kaprio J, Kreek MJ, Li MD, Munafò MR, Tyndale RF. Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clinical Pharmacology and Therapeutics. 88: 779-91. PMID 20981002 DOI: 10.1038/Clpt.2010.175 |
0.361 |
|
| 2009 |
Ho MK, Faseru B, Choi WS, Nollen NL, Mayo MS, Thomas JL, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 3426-34. PMID 19959692 DOI: 10.1158/1055-9965.Epi-09-0956 |
0.525 |
|
| 2009 |
Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology and Therapeutics. 85: 635-43. PMID 19279561 DOI: 10.1038/Clpt.2009.19 |
0.559 |
|
| 2008 |
Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human Mutation. 29: 679-88. PMID 18360915 DOI: 10.1002/Humu.20698 |
0.525 |
|
| 2008 |
Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenetics and Genomics. 18: 67-75. PMID 18216723 DOI: 10.1097/Fpc.0B013E3282F3606E |
0.52 |
|
| 2007 |
Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. The Pharmacogenomics Journal. 7: 81-98. PMID 17224913 DOI: 10.1038/sj.tpj.6500436 |
0.521 |
|
| Show low-probability matches. |